Latest News

Oslo, Norway, Photocure ASA (OSE: PHO), May 16, 2018, announced today the launch of Blue Light Cystoscopy (BLC™) with Cysview for a new indication of surveillance cystoscopy of bladder cancer.

Oslo, Norway, May 14th, 2018: Photocure ASA (PHO:OSE) announced today that Photocure will be exhibiting Blue Light Cystoscopy (BLC™) with Cysview in Booth 1825, during the American Urological Association Meeting (AUA 2018) in San Francisco, CA.

Your integrity is important to us in Photocure. Therefore, we update our Privacy Policy and Terms of Use so that you understand how we collect and use your information.

You receive this email because you are a subscriber to our news.

If you no longer wish to receive the news from us, please click on the unsubscribe link below.

Oslo, Norway, 9 May 2018: Photocure ASA (OSE: PHO), held its annual general meeting on 9 May 2018 at 17:00 hours (CET).

Princeton, New Jersey, May 3, 2018: Photocure ASA (OSE: PHO) is pleased to announce that Photocure will be presenting at the J.P. Morgan - Bio New Jersey Bio-Partnering meeting conference. The presentation will be held by Ambaw Bellete, President, Photocure Inc.

Oslo, 16 April 2018: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 9th May 2018 at 17:00 hours (CET).

Oslo, Norway, April 3rd, 2018, Photocure ASA (OSE: PHO), is pleased to announce that a new study on Blue Light Cystoscopy (BLC™) with Hexvix® using the KARL STORZ flexible videoscope system in the outpatient setting for the laser treatment of Low-Grade bladder tumors was published in Scandinavian Journal of Urology.

Oslo, Norway, March 20, 2018: Photocure ASA (OSE: PHO), is pleased to announce that Blue Light Cystoscopy (BLCTM) with Hexvix® was featured during the EAU annual meeting held in Copenhagen, Denmark, March 16th – 20th. The EAU is one of the largest international meetings in urology, attended by more than 12,000 urologists and exhibitors from over 110 countries.

Oslo, Norway, 27 February 2018: Photocure ASA (OSE:PHO), today reported a revenue growth of 27% for the important U.S. market in the fourth quarter of 2017, contributing to Hexvix®/Cysview® revenues of NOK 39.4 million (Q4 2016: NOK 31.6) and an EBITDA of NOK 0.9 million for the commercial franchise. With the reimbursement of Blue Light Cystoscopy with Cysview for Medicare patients and FDA approval of label expansion for Cysview, the company expects a continued solid growth towards the 2020 ambitions.

Photocure will present its fourth quarter and full year 2017 report on Tuesday 27 February 2018 at Hotel Continental, Oslo, Norway.

Oslo, Norway, February 16, 2018 Photocure ASA (OSE: PHO), announced today that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) to extend the indication for Blue Light Cystoscopy (BLC™) with Cysview® to include Flexible Cystoscopes, which are used in the ongoing surveillance of patients with bladder cancer. This is the only combination of drug and device approved for the detection of bladder cancer.

BLC with Cysview featured in Urology Time article January 26, 2018: “Role of blue light cystoscopy to detect bladder cancer”. Increased tumor detection, reduced recurrence/progression support its use in NMIBC patients.

Oslo, Norway, December 13, 2017 - Photocure ASA (OSE: PHO) announces today that the company will present at the DNB Nordic Healthcare Conference on 14th of December 2017 in Oslo, Norway.

Oslo, Norway, December 8, 2017: Photocure ASA (Photocure, PHO: OSE), today announced that the official Journal of the American Urologic Association (AUA), the Journal of Urology, published the efficacy results from a Phase 3 trial investigating the efficacy of Blue Light Cystoscopy (BLC^TM) with Cysview^® for surveillance with a flexible cystoscope. In 20,6 percent of patient's recurrence was seen only with BLC with Cysview and missed with WLC (p<0.0001).>

Oslo, Norway, December 1, 2017 Photocure ASA (OSE: PHO) announced today that more detailed data from the Phase 3 study data was presented at the prestigious Society of Urologic Oncology, Annual Meeting November 29 - December 01, 2017 in Washington D.C., USA. Four separate posters were presented, including one using patient reported outcomes (PRO) data from this study demonstrated the positive impact of Cysview on patient Quality of Life

A poster demonstrating the clinical and cost impact of Cevira^® was presented at the ISPOR European congress in Glasgow, Scotland, November 4-8, 2017. The budget impact model from a US payer perspective shows beneficial impact of replacing the current surgical modalities, LEEP and cold knife conization, with Cevira^®.

Oslo, Norway, 7 November 2017: Photocure ASA (OSE:PHO), today reported a revenue growth of 45% for the important US market in the third quarter of 2017, contributing to Hexvix/Cysview revenues of NOK 35.5 million (Q3 2016: NOK 31.6) and an EBITDA of NOK -0.2 million for the commercial franchise. Following the new Medicare reimbursement from 2018, Photocure increases the annual revenue ambition for 2020 to a range of USD 20 to 25 million.

Oslo, Norway, November 2, 2017: Photocure ASA (OSE: PHO), announced today that the United States Centers for Medicare & Medicaid Services (CMS) has issued a Final Rule stating that it will reimburse hospital outpatient departments for certain Blue Light Cystoscopy (BLC™) with Cysview^® procedures from January 1, 2018.

Photocure will present its third quarter report on Wednesday 8 November 2017 at Hotel Continental, Oslo, Norway.